Research programme: antibacterials - Quorex Pharmaceuticals

Drug Profile

Research programme: antibacterials - Quorex Pharmaceuticals

Alternative Names: QX5-1646 series antibacterials - Quorex; QX5-1799 series antibacterials - Quorex; QX5-1809 series antibacterials - Quorex

Latest Information Update: 25 May 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Quorex Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action DNA gyrase inhibitors; FabH inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 25 May 2010 No development reported - Preclinical for Bacterial infections in USA (unspecified route)
  • 12 Jul 2004 This programme is still in active development - BIO 2004 Annual International Convention (BIO-2004)
  • 30 Jan 2003 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top